Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968758 · ClinicalTrials.gov registry record · NA
Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains
A NA study of Clostridium Difficile Infection, sponsored by Meridian Bioscience.
- Completed
- Registry status
- NA
- Development phase
- 2,461
- Enrollment target
- 7
- Study locations
NCT02968758 is a NA study of Clostridium Difficile Infection that has completed, run by Meridian Bioscience. The registered enrollment target is 2,461 participants, below the 11,877-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (79% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT02968758, a NA study of Clostridium Difficile Infection, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,461 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this clinical investigation is to verify the performance of the GenePOC CDiff test on the GenePOC instrument. This will be achieved by comparing the GenePOC CDiff test to the Toxigenic Culture (TC) and cell cytotoxicity neutralisation assay (CCNA), a conventional method considered as gold standard for detection of toxigenic Clostridium difficile in stool specimens.
Conditions Studied
Interventions
- DEVICE Comparison between GenePOC PCR and Reference Method
Study Locations (7)
Indiana
- Wishard Health Services - Indianapolis
Maryland
- John Hopkins University School of Medicine - Baltimore
Michigan
- Detroit Medical Center University Laboratories - Detroit
New Mexico
- Tricore Laboratory University of New Mexico - Albuquerque
Wisconsin
- Medical College of Wisconsin - Milwaukee
Ontario
- Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex - Toronto
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,461 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2017-08-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968758
The ClinicalTrials.gov registry entry for NCT02968758 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,461 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,877-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (79% lower). The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 1 intervention - of which Comparison between GenePOC PCR and Reference Method is the first listed.
NCT02968758 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Indiana, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT02968758 about?
NCT02968758 is a clinical study titled "Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains". The primary purpose of this clinical investigation is to verify the performance of the GenePOC CDiff test on the GenePOC instrument. This will be achieved by comparing the GenePOC CDiff test to the Toxigenic Culture (TC) and cell cytotoxicity neutralisation assay (CCNA), a conventional method consid...
What is the current status of trial NCT02968758?
This trial is currently completed. It is a NA study. The enrollment target is 2,461 participants. The study started on 2017-02-06. Estimated completion is 2017-08-10.
What conditions does trial NCT02968758 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection.
What interventions are being tested in trial NCT02968758?
The interventions under investigation include: Comparison between GenePOC PCR and Reference Method (DEVICE).
Who is sponsoring clinical trial NCT02968758?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02968758 being conducted?
This trial has 7 study locations across Indiana, Maryland, Michigan, New Mexico, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
RECRUITING · NA
-
Fecal Microbiota Transplantation for C Diff Infection
RECRUITING · NA
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
Fecal Microbiota Transplant National Registry
RECRUITING
-
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
RECRUITING · Phase 2
-
Protocol for Admission Toxigenic C. Difficile Surveillance
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.